Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Pharmacology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Cancer Lett. 2014 Jan 1;342(1):104-12. doi: 10.1016/j.canlet.2013.08.040. Epub 2013 Sep 2.
Liposarcoma is the second most common soft tissue sarcoma in adults, but treatment options have been quite limited thus far. In this study, we investigated the functional and therapeutic relevance of cyclin-dependent kinase 11 (CDK11) as a putative target in liposarcoma. CDK11 knockdown by synthetic siRNA or lentiviral shRNA decreased cell proliferation, and induced apoptosis in liposarcoma cells. Moreover, CDK11 knockdown enhances the cytotoxic effect of doxorubicin to inhibit cell growth in liposarcoma cells. These findings suggest that CDK11 is critical for the growth and proliferation of liposarcoma cells. CDK11 may be a promising therapeutic target for the treatment of liposarcoma patients.
脂肪肉瘤是成人中第二常见的软组织肉瘤,但迄今为止,治疗选择相当有限。在这项研究中,我们研究了细胞周期蛋白依赖性激酶 11(CDK11)作为脂肪肉瘤潜在靶点的功能和治疗相关性。通过合成 siRNA 或慢病毒 shRNA 敲低 CDK11 可降低脂肪肉瘤细胞的增殖,并诱导细胞凋亡。此外,CDK11 敲低增强阿霉素的细胞毒性作用,从而抑制脂肪肉瘤细胞的生长。这些发现表明 CDK11 对脂肪肉瘤细胞的生长和增殖至关重要。CDK11 可能是治疗脂肪肉瘤患者的有前途的治疗靶点。